This is to inform that due to some circumstances beyond the organizer control, "3rd Edition of International Precision Medicine Conference" (IPMC 2023) scheduled during April 24-26, 2023 in Orlando, Florida, USA has been postponed. The updated dates and venue will be displayed shortly.
Your registration can be transferred to the next edition, if you have already confirmed your participation at the event.
For further details, please contact us at [email protected] or call + 1 (702) 988 2320.
Biomarkers and diagnostics are critical components in diagnosing a disease or pathogenic process, monitoring patients throughout treatment, and determining patient response to an exposure or therapy. Biomarkers and diagnostics are used in precision medicine to predict and monitor patient response to medicines, or to identify different sub-populations of patients who are most likely to benefit from pre-determined treatments. Any biological indicator that can be measured can be used as a biomarker. Biomarkers can be quantitative or qualitative in nature. In a yes/no analysis, qualitative biomarkers may be used to detect pathogenic processes, whereas quantitative biomarkers are used to detect pathogenic processes with a threshold effect.
Title : Copper (II) complexes as potential anticancer agents
Salah S Massoud, University of Louisiana, United States
Title : Leveraging blockchain technology, edge computing and federated learning to enhance outcomes in precision medicine
Ingrid Vasiliu Feltes, MEDNAX, United States
Title : The new horizons in the patient- centered care for understanding of the reasons of its health problems – Psychosynthesis approach
Ewa Danuta Bialek, Institute of Psychosynthesis, Poland
Title : Hegazy theory for interpretation of human parthenogenesis: A new hypothesis
Abdelmonem Awad Hegazy, Zagazig University, Egypt
Title : Precision Oncology and Personalised Medicine: Innovative Technology for the Treatment of Colorectal Cancer
Huiqin Yang, ICON Clinical Research Ltd, United Kingdom
Title : The role of CD44v6 as a new immunotherapy target for urothelial cancer
Iris Adriana Maria Lodewijk, Institute of Biomedical Research, Spain